Lumos Diagnostics Holdings Ltd.

As of June 30, 2026, Lumos Diagnostics Holdings Ltd. carries a market capitalization of 99.16M, placing it among publicly traded companies globally. Its enterprise value stands at 85.45M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Lumos Diagnostics Holdings Ltd.'s next confirmed earnings release is scheduled for March 4, 2027.

As of June 30, 2026, Lumos Diagnostics Holdings Ltd. has 944.39M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 4.48, and the price-to-book ratio stands at 3.00.

These figures are as of June 30, 2026. The EV/Sales ratio of 4.48 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 85.45M versus a market cap of 99.16M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Lumos Diagnostics Holdings Ltd. maintains a current ratio of 1.52, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 25.98, indicating elevated leverage, while an interest coverage ratio of -3.38 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Lumos Diagnostics Holdings Ltd. posted a negative return on equity (ROE) of -34.13, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -16.09, reflecting losses generated across the asset base. Inventory turnover of 4.87 indicates how many times Lumos Diagnostics Holdings Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Lumos Diagnostics Holdings Ltd.'s stock has declined approximately 64.68% over the past 52 weeks. The 50-day moving average sits at 0.10, while the 200-day moving average is 0.16.

Over the twelve months ended June 30, 2026, Lumos Diagnostics Holdings Ltd. generated 19.06M in revenue and converted that into -7.16M in net income, yielding earnings per share of -0.01. EBITDA reached -7.61M, while operating income came in at -20.34M.

As of June 30, 2026, Lumos Diagnostics Holdings Ltd. holds 22.29M in cash and equivalents against 8.58M in total debt, resulting in a net debt position of -22.29M. Total book value stands at 33.03M, with working capital of 9.82M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Lumos Diagnostics Holdings Ltd. posted a gross margin of 60.12, reflecting its pricing power and cost economics. The operating margin of -106.69 and net profit margin of -37.54 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Total shareholder yield is negative at -22.19, meaning Lumos Diagnostics Holdings Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Lumos Diagnostics Holdings Ltd.'s most recent stock split took place on September 6, 2024 with a 213:227 split ratio.

As of June 30, 2026, Lumos Diagnostics Holdings Ltd. has an Altman Z-Score of -3.90, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.